Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Calmus

Showing results (21-30 of 143) with videos related to

Pageof 15
Sort By:
Revue De L'Infirmiere|January 1, 1984
[Who should be vaccinated against the hepatitis B virus currently in France?]J C Barbare, Y Calmus, F Darnis
Journal De Chirurgie|July 27, 2001
[Liver transplantation for alcoholic liver disease]P Podevin, G Vidal-Trécan, Y Calmus
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris|October 20, 1983
[Who should currently be vaccinated against hepatitis B virus in France?]J C Barbare, Y Calmus, F Darnis
Presse Medicale (Paris, France : 1983)|November 19, 1983
[Urinary lithiasis secondary to intestinal diseases]Y Calmus, J P Gendre, F Mignon
Hepatology (Baltimore, Md.)|January 1, 1990
Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acidY Calmus, P Gane, P Rouger, et al.
Therapie|July 1, 1992
[Hepatic allograft rejection. Diagnostic and therapeutic aspects]Y Calmus, F Conti, B Dousset, et al.
Journal of Hepatology|April 1, 1993
Preservation-induced liver injury. Clinical aspects, mechanisms and therapeutic approachesO Chazouillères, Y Calmus, M Vaubourdolle, et al.
Journal of Hepatology|April 1, 1994
Differential effects of chenodeoxycholic and ursodeoxycholic acids on expression of procoagulant activity by human monocytesY Calmus, P Podevin, A Robert, et al.
The New England Journal of Medicine|April 21, 1994
Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipientsB Dousset, F Conti, D Houssin, et al.
Gastroenterologie Clinique Et Biologique|December 1, 1986
[Tolerance of hepatic allografts]Y Calmus, B Weill, I Amar, et al.
Pageof 15

Showing results (21-30 of 143) with videos related to

Sort By:
Pageof 15
Revue De L'Infirmiere|January 1, 1984
[Who should be vaccinated against the hepatitis B virus currently in France?]J C Barbare, Y Calmus, F Darnis
Journal De Chirurgie|July 27, 2001
[Liver transplantation for alcoholic liver disease]P Podevin, G Vidal-Trécan, Y Calmus
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris|October 20, 1983
[Who should currently be vaccinated against hepatitis B virus in France?]J C Barbare, Y Calmus, F Darnis
Presse Medicale (Paris, France : 1983)|November 19, 1983
[Urinary lithiasis secondary to intestinal diseases]Y Calmus, J P Gendre, F Mignon
Hepatology (Baltimore, Md.)|January 1, 1990
Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acidY Calmus, P Gane, P Rouger, et al.
Therapie|July 1, 1992
[Hepatic allograft rejection. Diagnostic and therapeutic aspects]Y Calmus, F Conti, B Dousset, et al.
Journal of Hepatology|April 1, 1993
Preservation-induced liver injury. Clinical aspects, mechanisms and therapeutic approachesO Chazouillères, Y Calmus, M Vaubourdolle, et al.
Journal of Hepatology|April 1, 1994
Differential effects of chenodeoxycholic and ursodeoxycholic acids on expression of procoagulant activity by human monocytesY Calmus, P Podevin, A Robert, et al.
The New England Journal of Medicine|April 21, 1994
Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipientsB Dousset, F Conti, D Houssin, et al.
Gastroenterologie Clinique Et Biologique|December 1, 1986
[Tolerance of hepatic allografts]Y Calmus, B Weill, I Amar, et al.
Pageof 15